7 research outputs found
Chemotherapy-induced peripheral neuropathy onset is associated with early risk of depression and anxiety in breast cancer survivors
ObjectiveThe objective was to assess for an association between chemotherapy-induced peripheral neuropathy (CIPN) onset and development of depression and anxiety in breast cancer (BrCa) survivors.MethodsA retrospective observational cohort was used and identified from Optumâs De-identified ClinformaticsÂź Data Mart Database years 2012â2015. Three groups of women were derived based on BrCa and CIPN status: BrCa+/CIPN+ (nâ=â244), BrCa+/CIPNâ (nâ=â8870), and BrCaâ/CIPNâ (nâ=â1,125,711). The ratio of the prevalence ratios (RPR) determined if the change in risk of depression and anxiety from the 12-month preindex period to postindex period I (0â6Â months) and II (7â12âmonths) was different for BrCa+/CIPN+ compared to BrCa+/CIPNâ and BrCaâ/CIPNâ.ResultsThe adjusted RPR for depression was significantly elevated for BrCa+/CIPN+ compared to BrCa+/CIPNâ and BrCaâ/CIPNâ for postindex periods I (RPRâ=â1.35 [1.10,1.65] and 1.33 [1.08,1.63], respectively) and II (RPRâ=â1.53 [1.21,1.94] and 1.50 [1.17,1.93], respectively). The RPR for anxiety was significantly elevated for BrCa+/CIPN+ compared to BrCa+/CIPNâ and BrCaâ/CIPNâ for postindex periods I (RPRâ=â1.37 [1.12,1.67] and 1.31 [1.06,1.61], respectively) and II (RPRâ=â1.41 [1.13,1.76] and 1.28 [1.02,1.62], respectively).ConclusionsAmong BrCa survivors, CIPN onset is associated with a subsequent increased 12-month risk of depression and anxiety. Depression and anxiety screening should be considered in BrCa+/CIPN+ survivors, particularly given their known impact on fall risk. The observed association between CIPN and an increased risk of depression and anxiety should be further studied in prospective studies.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/175183/1/ecc13648_am.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/175183/2/ecc13648.pd
Chemotherapyâinduced peripheral neuropathy increases nontraumatic fracture risk in breast cancer survivors
Chemotherapy is a common treatment for breast cancer (BrCa) and can cause chemotherapyâinduced peripheral neuropathy (CIPN). CIPN contributes to falls, and is thus a potential risk factor for nontraumatic fractures (NTFx); yet, the effect of CIPN on NTFx risk has not been examined for BrCa survivors. We therefore investigated the association between CIPN and NTFx in BrCa survivors. Data were extracted from Optumâs Deidentified ClinformaticsÂź Data Mart Database years 2010â2015 in this retrospective cohort study. Among women, three groups were derived based on BrCa and CIPN status: BrCa+/CIPN+ (primary group of interest), BrCa+/CIPNâ (first comparison group), and BrCaâ/CIPNâ (second comparison group). After propensity score matching the comparison groups to BrCa+/CIPN+ at a ratio of 1:11 (BrCa:control) for demographics, osteoporosis, glucocorticoid medication, comorbidities, and cancerârelated variables for BrCa+/CIPNâ, 1âyear incidence rate (IR) of NTFx was determined for each group. The incident rate ratio (IRR) determined if the IR for NTFx was different for BrCa+/CIPN+ compared to BrCa+/CIPNâ and BrCaâ/CIPNâ. Cox proportional hazards regression models estimated the hazard ratios (HRs) after adjusting for covariates that were unable to be matched for. The crude IR (95% confidence interval [CI]) of NTFx was 4.54 (2.32â6.77) for BrCa+/CIPN+ (n = 359), 2.53 (2.03â3.04) for BrCa+/CIPNâ (n = 3949), and 1.76 (1.35â2.18) for BrCaâ/CIPNâ (n = 3949). The crude IRR of NTFx was significantly elevated for BrCa+/CIPN+ as compared to BrCa+/CIPNâ (IRR = 1.80; 95% CI, 1.06â3.05) and BrCaâ/CIPNâ (IRR = 2.58; 95% CI, 1.50â4.44). The elevated rate of NTFx for BrCa+/CIPN+ remained unchanged after adjusting for aromatase inhibitors compared to BrCa+/CIPNâ (HR = 1.79; 95% CI, 1.06â3.04). Female BrCa survivors have an increased 1âyear IR of NTFx after the onset of CIPN, suggesting that CIPN is an additive burden on NTFx risk among BrCa survivors. © 2021 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/168516/1/jbm410519.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/168516/2/jbm410519_am.pd
Recommended from our members
Associations Between Circulating Levels of Myostatin and Plasma ÎČ-Amyloid 42/40 in a Biracial Cohort of Older Adults.
BACKGROUND: Myostatin, a cytokine produced by skeletal muscle, may influence Alzheimers disease (AD) pathogenesis, but sparse evidence exists in humans. We assessed the association between circulating levels of myostatin at Year 1 and plasma levels of ÎČ-amyloid 42/40 at Year 2, a marker of AD pathology, in a biracial cohort of older adults. METHODS: We studied 403 community-dwelling older adults enrolled in the Health, Aging and Body Composition Study from Memphis, Tennessee, and Pittsburgh, PA. Mean age was 73.8 ± 3 years; 54% were female; and 52% were Black. Serum myostatin levels were measured at Year 1, plasma ÎČ-amyloid 42/40 levels in Year 2 (higher ratio indicating lower amyloid load). Multivariable linear regression analyses tested the association of serum myostatin with plasma levels of ÎČ-amyloid 42/40 adjusted for computed-tomography-derived thigh muscle cross-sectional area, demographics, APOe4 allele, and risk factors for dementia. We tested for 2-way.interactions between myostatin and race or sex; results were stratified by race and sex. RESULTS: In multivariable models, myostatin was positively associated with plasma levels of ÎČ-amyloid 42/40 (standardized regression coefficient: 0.145, p = .004). Results were significant for white men and women (0.279, p = .009, and 0.221, p = .035, respectively) but not for Black men or women; interactions by race and gender were not statistically significant. CONCLUSIONS: Higher serum myostatin was associated with lower amyloid burden, independently of APOe4 alleles, muscle area and other established risk factors for dementia. The role of myostatin in AD pathogenesis and the influence of race should be further investigated
Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: systematic review and evidence-based recommendations
: Pharmacological strategies for chemotherapy-induced peripheral neurotoxicity (CIPN) are very limited. We systematically reviewed data on rehabilitation, exercise, physical therapy, and other physical non-pharmacological interventions and offered evidence-based recommendations for the prevention and treatment of CIPN. A literature search using PubMed, Web of Science and CINAHL was conducted from database inception until May 31st, 2021. 2791 records were title-abstract screened, 71 papers were full-text screened, 41 studies were included, 21 on prevention and 20 on treatment of CIPN. Treatment type, cancer type, chemotherapy compounds were heterogeneous, sample size was small (median: N\u2009=\u200934) and intention-to-treat analysis was lacking in 26/41 reports. Because of the methodological issues of included studies, the reviewed evidence should be considered as preliminary. Exercise, endurance, strength, balance, and sensorimotor training have been studied in low-to-moderate quality studies, while the evidence for other treatments is preliminary/inconclusive. We offer recommendation for the design of future trials on CIPN